Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 21

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
,209 Restricted Stock UnitsRestricted stock units (“RSUs”) activity for the nine months ended September 30, 2025 is as follows:Restricted StockUnitsWeighted-AverageGrant Date Fair Value(per share)Outstanding as of December 31, 20246,493,387 $35.55 Granted5,579,963 10.49 Vested(2,267,488)32.54 Cancelled(1,339,829)28.24 Outstanding as of September 30, 20258,466,033 $21.00 Stock OptionsStock option activity for the nine months ended September 30, 2025 is as follows:Stock OptionsWeighted-AverageExercise PriceOutstanding as of December 31, 20244,594,582 $45.37 Exercised(433,463)2.54 Cancelled and forfeited(460,484)66.32 Outstanding as of September 30, 20253,700,635 $47.78 Performance Stock Awards In March 2025, the Company granted 561,603 performance stock units (“PSUs”) under the 2019 Omnibus Incentive Plan (“2019 plan”) to certain members of management which are subject to the achievement of certain performance conditions established by the Company’s Compensation Committee of the Board of Directors as described below:i.50% of target PSUs earned will be based on the Company’s compound annual growth rate (“CAGR”) of the Company’s Revenue over a two-year performance period from January 1, 2025 to December 31, 2026. Holders may earn from 0% to 200% of the target amount of shares and earned PSUs will then be subject to service-based vesting; andii.50% of target PSUs earned will be based on the relative Total Shareholder Return (“TSR”) of the Company’s Class A common stock as compared to the TSR of the members of the Russell 3000 Medical Equipment and Services Sector Index over a three-year performance period from January 1, 2025 to December 31, 2027. Depending on the results relative to the TSR market condition, the holders may earn from 0% to 200% of the target amount of shares which will vest at the end of the performance period.

17

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated